Neuphoria Therapeutics rises on $15 mln milestone payment from Merck

Neuphoria Therapeutics

12/02/2025 15:50

** Massachusetts-based drug developer Neuphoria Therapeutics
 NEUP.O  rises 3.31% to $4.65 in morning trade 
    ** Co, which develops treatments for brain and mental health
disorders, says it is due to receive $15 million milestone
payment from Merck  MRK.N  
    ** The payment is triggered by the start of a mid-stage
study for the treatment of Merck's Alzheimer's disease dementia
    ** The study is estimated to complete on July 20, 2027
    ** The study is to test if the experimental drug, MK-1167,
given along with another therapy that affects memory, which can
improve symptoms of Alzheimer's disease dementia such as memory
and mental activity
    ** NEUP is eligible to receive up to $450 million in
additional milestone payments if certain developments are
achieved 
    ** In the last 12 months, the stock down 70%

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))